262 related articles for article (PubMed ID: 36990277)
21. Metastatic Undifferentiated Melanoma Mimicking a Primary Bone Tumor: A Potential Diagnostic Pitfall.
Wills A; Dibbern M; Frierson HF; Raghavan SS
Am J Dermatopathol; 2024 Mar; 46(3):170-172. PubMed ID: 38170737
[TBL] [Abstract][Full Text] [Related]
22. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma.
Alrabadi N; Gibson N; Curless K; Cheng L; Kuhar M; Chen S; Warren SJP; Alomari AK
Mod Pathol; 2019 Mar; 32(3):330-337. PubMed ID: 30315274
[TBL] [Abstract][Full Text] [Related]
23. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.
Francis P; Namløs HM; Müller C; Edén P; Fernebro J; Berner JM; Bjerkehagen B; Akerman M; Bendahl PO; Isinger A; Rydholm A; Myklebost O; Nilbert M
BMC Genomics; 2007 Mar; 8():73. PubMed ID: 17359542
[TBL] [Abstract][Full Text] [Related]
25. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
28. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.
Cammareri C; Beltzung F; Michal M; Vanhersecke L; Coindre JM; Velasco V; Le Loarer F; Vergier B; Perret R
Virchows Arch; 2023 Aug; 483(2):145-156. PubMed ID: 37477762
[TBL] [Abstract][Full Text] [Related]
29. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
[TBL] [Abstract][Full Text] [Related]
30. The many faces of Atypical fibroxanthoma.
Agaimy A
Semin Diagn Pathol; 2023 Jul; 40(4):306-312. PubMed ID: 37438163
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.
Roland CL; May CD; Watson KL; Al Sannaa GA; Dineen SP; Feig R; Landers S; Ingram DR; Wang WL; Guadagnolo BA; Feig B; Hunt KK; Cormier JN; Lazar AJ; Torres KE
Ann Surg Oncol; 2016 Jul; 23(7):2220-8. PubMed ID: 26847678
[TBL] [Abstract][Full Text] [Related]
32. Molecular Markers and Targets in Melanoma.
Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
[TBL] [Abstract][Full Text] [Related]
33. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive molecular profile of primary cutaneous epithelioid rhabdomyosarcoma: A tumor genomically and molecularly related to malignant melanoma.
Shafi S; Shah M; Jones D; Beane JD; Oghumu S; Iwenofu OH
Genes Chromosomes Cancer; 2023 Nov; 62(11):678-684. PubMed ID: 37357966
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expression of melanocytic and myofibroblastic markers and their molecular correlation in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Mauch C; Buettner R; Quaas A
J Cutan Pathol; 2018 Dec; 45(12):880-885. PubMed ID: 30155964
[TBL] [Abstract][Full Text] [Related]
36. Undifferentiated Sarcoma as Intermediate Step in Rhabdomyosarcomatous Transformation of a Metastatic Malignant Melanoma Resistant to Anti-BRAF Therapy: A Phenomenon Associated With Significant Diagnostic and Therapeutic Pitfalls.
Tran TAN
Int J Surg Pathol; 2019 Sep; 27(6):669-677. PubMed ID: 30942107
[TBL] [Abstract][Full Text] [Related]
37. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
38. Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.
Zheng B; Qu Y; Wang J; Shi Y; Yan W
Cancer Genomics Proteomics; 2019; 16(3):221-228. PubMed ID: 31018952
[TBL] [Abstract][Full Text] [Related]
39. High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event.
Rüping K; Altendorf-Hofmann A; Chen Y; Kampmann E; Gibis S; Lindner L; Katenkamp D; Petersen I; Knösel T
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1315-22. PubMed ID: 24804818
[TBL] [Abstract][Full Text] [Related]
40. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
